Search results for "Combinations"

showing 10 items of 204 documents

Algorithms for {K, s+1}-potent matrix constructions

2013

In this paper, we deal with {K, s + 1}-potent matrices. These matrices generalize all the following classes of matrices: k-potent matrices, periodic matrices, idempotent matrices, involutory matrices, centrosymmetric matrices, mirrorsymmetric matrices, circulant matrices, among others. Several applications of these classes of matrices can be found in the literature. We develop algorithms in order to compute {K, s + 1}-potent matrices and {K, s + 1}-potent linear combinations of {K, s + 1}-potent matrices. In addition, some examples are presented in order to show the numerical performance of the method. (C) 2012 Elsevier B.V. All rights reserved.

Matemàtica aplicadaQuantitative Biology::BiomoleculesLinear combinationsQuantitative Biology::Populations and EvolutionEigenvaluesPotent matricesINGENIERIA TELEMATICAMATEMATICA APLICADAMatrius (Matemàtica)Involutory matricesQuantitative Biology::Cell Behavior
researchProduct

Histological and histomorphometrical analysis of a silica matrix embedded nanocrystalline hydroxyapatite bone substitute using the subcutaneous impla…

2010

The clinical suitability of a bone substitute material is determined by the ability to induce a tissue reaction specific to its composition. The aim of this in vivo study was to analyze the tissue reaction to a silica matrix-embedded, nanocrystalline hydroxyapatite bone substitute. The subcutaneous implantation model in Wistar rats was chosen to assess the effect of silica degradation on the vascularization of the biomaterial and its biodegradation within a time period of 6 months. Already at day 10 after implantation, histomorphometrical analysis showed that the vascularization of the implantation bed reached its peak value compared to all other time points. Both vessel density and vascula…

Materials scienceBone substituteBiomedical Engineering2204 Biomedical EngineeringBioengineering610 Medicine & healthBiomaterialsSubcutaneous TissueIn vivoAbsorbable ImplantsMaterials TestingAnimalsRats WistarBone regeneration11077 Center for Applied Biotechnology and Molecular Medicine1502 Bioengineering2502 BiomaterialsBiomaterialSilicon DioxideNanocrystalline materialRatsDrug CombinationsDurapatiteGiant cellSilica matrixBone SubstitutesSubcutaneous implantationNanoparticlesFemaleBiomedical engineeringBiomedical materials (Bristol, England)
researchProduct

The Use of Atomic Force Microscopy in Determining the Stiffness and Adhesion Force of Human Dentin After Exposure to Bleaching Agents

2009

Introduction: Oxidant bleaching agents may induce several alterations on mineralized teeth tissues. Our aim is to study,at the ultrastructurallevel,mechanicalmodifications induced on dentin after exposure to different bleaching agents.Methods: Nanoindentation performed with atomic force microscopy was used to measure changes in dentin stiffness as well as the adhesion force between the tip and the tissue both in intertubular and peritubulardentin.Foreachspecimen,dentinlocalization, and bleaching agent, 100 independent nanoindentations were performed. Carbamide peroxide (30%) and hydrogenperoxide(35%) wereusedasbleaching agents. Results: A significant reduction of both stiffness and adhesion…

Materials scienceDentistryCarbamide PeroxideMicroscopy Atomic Forcechemistry.chemical_compoundstomatognathic systemHardnessElastic ModulusMaterials TestingImage Processing Computer-AssistedTooth BleachingmedicineDentinHumansUreaAdhesion forceHydrogen peroxideGeneral DentistryAtomic force microscopybusiness.industryStiffnessHydrogen PeroxideNanoindentationOxidantsPeroxidesDrug Combinationsmedicine.anatomical_structurechemistryIntertubular dentinDentinStress Mechanicalsense organsCarbamide peroxidemedicine.symptombusinessAlgorithmsBiomedical engineeringJournal of Endodontics
researchProduct

Long-term sealing ability of GuttaFlow versus Ah Plus using different obturation techniques.

2010

Objective. To compare the long-term sealing ability of GuttaFlow® using different obturation techniques. Study Design. Three hundred teeth, prepared with a crown-down technique, were divided into thirty experimental groups (n=10) to evaluate the apical and coronal leakage, at 3, 30 and 120 days, of lateral compaction gutta-percha + AH Plus?, lateral compaction gutta-percha + GuttaFlow®, single cone + AH Plus?, single cone + GuttaFlow®, and GuttaFlow® only. Results. Both coronal and apical leakage, at the three times of measurement, no significant differences were found among GuttaFlow® + lateral compaction gutta-percha and GuttaFlow® + single cone groups, whereas the only GuttaFlow® reached…

Materials scienceTime FactorsEpoxy ResinsCompactionApical leakage:CIENCIAS MÉDICAS [UNESCO]Silicon basedRoot Canal Filling MaterialsDrug CombinationsOtorhinolaryngologyRoot Canal ObturationCoronal planeUNESCO::CIENCIAS MÉDICASMaterials TestingHumansSurgerySingle coneDimethylpolysiloxanesGutta-PerchaGeneral DentistryLeakage (electronics)Biomedical engineeringMedicina oral, patologia oral y cirugia bucal
researchProduct

Withdrawal of a mumps vaccine: Reasons and impacts

1993

Measles-Mumps-Rubella Vaccinebusiness.industryMeasles VaccineInfantMumps VaccineVirologyMeningitis BacterialDrug CombinationsRubella vaccineMumps vaccineChild PreschoolPediatrics Perinatology and Child HealthProduct Surveillance PostmarketingmedicineHumansRubella VaccineMeasles vaccineViral diseasebusinessMeasles-Mumps-Rubella VaccineCerebrospinal FluidRetrospective Studiesmedicine.drugEuropean Journal of Pediatrics
researchProduct

Anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing chemotherapy.

2000

OBJECTIVE: To characterize the effects of anthropometric and pharmacotherapeutic variables on acute emesis induced by cisplatin-containing regimens with dosages ·50 mg·m−2. METHODS: A prospective, cross-sectional, noncontrolled study was performed to analyze acute vomiting during the first 24 hours in patients treated in a Spanish hospital. The patients received an intravenous combination of drugs (2 doses of metoclopramide 3 mg/kg, dexamethasone 20 mg) as first-choice antiemetic therapy. Intravenous ondansetron 8 mg and dexamethasone 20 mg served as an alternative regimen in patients <30 years old with a history of extrapyramidal manifestations or emesis in previous cycles. Therapeutic …

Metoclopramidemedicine.drug_classChlorpromazineMetoclopramideVomitingmedicine.medical_treatmentAntineoplastic Agents030204 cardiovascular system & hematology030226 pharmacology & pharmacyDexamethasoneOndansetron03 medical and health sciences0302 clinical medicineSex FactorsOrphenadrinemedicineAntiemeticHumansPharmacology (medical)Body Weights and MeasuresProspective StudiesDexamethasoneChemotherapybusiness.industryAge FactorsMiddle AgedPrognosisOndansetronRegimenDrug CombinationsCross-Sectional StudiesLogistic ModelsAnesthesiaAcute DiseaseMultivariate AnalysisVomitingCorticosteroidAntiemeticsmedicine.symptomCisplatinbusinessmedicine.drugThe Annals of pharmacotherapy
researchProduct

Contribution of outgrowth endothelial cells from human peripheral blood on in vivo vascularization of bone tissue engineered constructs based on star…

2009

In the present study we assessed the potential of human outgrowth endothelial cells (OEC), a subpopulation within endothelial progenitor cell cultures, to support the vascularization of a complex tissue engineered construct for bone. OEC cultured on starch polycaprolactone fiber meshes (SPCL) in monoculture retained their endothelial functionality and responded to angiogenic stimulation by VEGF (vascular endothelial growth factor) in fibrin gel-assays in vitro. Co-culture of OEC with human primary osteoblasts (pOB) on SPCL, induced an angiogenic activation of OEC towards microvessel-like structures achieved without additional supplementation with angiogenic growth factors. Effects of co-cul…

Mice SCID02 engineering and technologyBone tissueBone tissue engineeringNeovascularizationMicechemistry.chemical_compoundSubcutaneous TissueImplants ExperimentalTissue engineeringOsteogenesisEndothelial progenitor cells0303 health sciencesIn vivo testTissue ScaffoldsbiologyStarch021001 nanoscience & nanotechnology3. Good healthCell biologyVascular endothelial growth factorDrug CombinationsPhenotypemedicine.anatomical_structureMechanics of MaterialsProteoglycansCollagenmedicine.symptom0210 nano-technologyPolyestersBiophysicsNeovascularization PhysiologicBioengineeringEndothelial progenitor cellBone and BonesFibrinBiomaterials03 medical and health sciencesIn vivomedicineAnimalsHumansCell Proliferation030304 developmental biologyMatrigelScience & TechnologyOsteoblastsTissue EngineeringVascularizationEndothelial CellsCoculture TechniquesGene Expression RegulationchemistryCeramics and Compositesbiology.proteinLamininBiomedical engineeringBiomaterials
researchProduct

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct

New β-Lactam-β-Lactamase Inhibitor Combinations.

2020

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, an…

Microbiology (medical)DrugImipenemBacilliEpidemiologyKlebsiella pneumoniaemedia_common.quotation_subjectMicrobial Sensitivity Testsmedicine.disease_causebeta-LactamsMeropenemMicrobiologyDrug Resistance Multiple BacterialGram-Negative Bacteriapolycyclic compoundsmedicinemedia_commonGeneral Immunology and MicrobiologybiologyPseudomonas aeruginosabusiness.industryPublic Health Environmental and Occupational Healthbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationCeftazidime/avibactamAcinetobacter baumanniiDrug CombinationsInfectious DiseasesbacteriaErratumbusinessbeta-Lactamase Inhibitorsmedicine.drugClinical microbiology reviews
researchProduct